• 16.02.2019 – 23:10

  Merck KGaA

  Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

• 11.02.2019 – 23:55

  Merck KGaA

  FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

• 11.09.2018 – 14:31

  Merck KGaA

  BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...